GoKawiilFDA scientists resisted RFK Jr.-backed push to ease peptide drug access
FDA scientific staff largely opposed a policy that would have made it easier for Americans to obtain unproven peptide drugs favored by Health Secretary Robert F. Kennedy Jr., according to six people familiar with its development. Agency officials reportedly warned that career scientists had serious safety concerns and would not endorse a regulation declaring the peptides safe, and staff said they had limited input in drafting the policy.
GoKawiil's interpretation of the reporting above, not reported fact.
The reported internal dissent suggests a divide between political leadership at HHS and the FDA's scientific ranks over how much risk is acceptable in expanding access to supplements or therapies lacking rigorous safety data. If accurate, this could signal broader tension over how evidence-based decisions are made under the current administration, and may invite scrutiny from Congress or watchdog groups if the policy advances despite scientific objections.
- FDA scientific staff reportedly opposed easing access to unproven peptide drugs
- Six sources say staff had limited input in shaping the policy
- The policy was linked to Health Secretary Robert F. Kennedy Jr.'s preferences
Source: fastcompany.com, 2026-10-28
Published there as: “How FDA scientists opposed the Trump administration’s push for easier access to peptides”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.